Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of HPV-16/18 AS04 vaccine with Boostrix Polio in healthy girls aged 10-18 years
2006-003807-38Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and Boostrix Polio in human papillomavirus infection and Cervical Cancer (CC) (3 arms), sponsored by GSK. Primary endpoints: Anti-diphtheria and anti-tetanus seroprotection one month after dTpa-IPV, Non-inferiority of dTpa-IPV immune response with co-administration and 1 more. Started Dec 2006; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenBoostrix Polio
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2006-003807-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003807-38.